NRx Pharmaceuticals (NRXP) Quarterly EPS earnings growth

nrxpharma.com - graphic logo of issuer NRXP

NRx Pharmaceuticals (NRXP) generates revenue by developing treatments for suicidal depression and pulmonary infections. However, a narrow pipeline of products creates risks that are offset by its breakthrough therapy status. The current quarterly EPS growth rate allows for a real-time assessment of development dynamics, while the 80.70 metric confirms the current level. These processes are further supported by the implementation of ESG standards in drug synthesis and strict ethical oversight.

NRx Pharmaceuticals, Inc. (NRXP) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 11/18/2026

Comprehensive metric breakdowns and analytics for nrxpharma.com (NRXP)

- share price and consensus valuation forecast:
Summary company analytics:NRx Pharmaceuticals, NRXP
Manufactured product of NRx Pharmaceuticals

This indicator measures the quarterly dynamics of earnings per share, allowing investors to filter out market noise from actual business performance. By analyzing the quarterly EPS growth index, an investor can determine the revenue stability of NRx Pharmaceuticals (NRXP), which depends critically on the cost of third-party CRO and CMO services during the development of antidepressants.

Key competitors

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharma (AVDL)|ATAI (atai.life) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research PLC (GHRS)|Quarterly EPS earnings growth MNMD|CMPS (COMPASS Pathways PLC) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months lbpharma.us LBRX|Bright Minds Biosciences Inc (DRUG) - Earnings per share growth in annualized terms for the last twelve months|VNDA: Year-over-year net earnings per share growth for the last 12 months|Cybin Inc (CYBN) - Year-over-year net earnings per share growth for the last 12 months|Alto Neuroscience (ANRO) - Year-over-year earnings per share growth for the last twelve months|CING - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma, Inc.|chinapharmaholdings.com (CPHI) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CMND|Psyence Biomedical Ltd. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Seelos Therapeutics Inc. (SEEL) - Earnings per share growth in annualized terms for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth